Skip to Main Content
Contribute Try STAT+ Today

In a notable development, the first long-acting injectable shot for preventing HIV was approved by the Food and Drug Administration this week, ushering in what could be a new era in the battle against AIDS.

The medicine, which is called Apretude, offers a significant advancement in combating what continues to be a highly infectious disease. In 2019, approximately 36,800 people in the U.S. were diagnosed with HIV and an estimated 34,800 were infected that same year, according to the latest data from the federal government. As many as 1.2 million Americans, meanwhile, are believed to be living with the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment